摘要
Abstract
Objective:To probe into the clinical efficacy of recombinant human erythropoietin in treatment of neonatal hypoxic ischemic encephalopathy.METHODS: 66 patients with neonatal hypoxic ischemic encephalopathy admitted into Ezhou Maternal and Child Health Care Hospital from Sept.2015 to Aug.2016 were extracted to be divided into observation group and control group via the random number table,with 33 cases in each.The control group was given conventional treatment,while the observation group additionally received recombinant human erythropoietin based on the control group.After treatment of two weeks,the neonatal behavioral neurological assesssment of two groups were recorded,differences of psychomotor development index(PDI)and mental development index(MDI)of two groups were compared.RESULTS: After treatment of two weeks,the neonatal behavioral neurological assesssment of observation group was significantly better than that of control group,with statistically significant difference(P<0.05).At the age of three and six months,the PDI and MDI in observation group were better than those in control group,with statistically significant difference(P<0.05).CONCLUSIONS: The efficacy of recombinant human erythropoietin in treatment of neonatal hypoxic ischemic encephalopathy is remarkable,which can effectively promote the motor ability and intelligence of children.关键词
缺氧缺血性脑病/新生儿/促进细胞生成素/临床疗效Key words
Hypoxic ischemic encephalopathy/Newborn/Recombinant human erythropoietin/Clinical Efficacy分类
医药卫生
